Improving Breast Cancer Sensitivity to Paclitaxel by Increasing Aneuploidy
Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy Sylvie Rodrigues-Ferreiraa,1, Anne Nehliga, Hadia Moindjiea, Clarisse Monchecourta, Cynthia Seilera, Elisabetta Marangonib, Sophie Chateau-Joubertc, Marie-Eglantine Dujaricd, Nicolas Servante, Bernard Asselaind, Patricia de Cremouxf, Magali Lacroix-Trikig, Monica Arnedosg, Jean-Yves Piergah, Fabrice Andréa,g, and Clara Nahmiasa,2 aINSERM U981, LabEx LERMIT, Department of Molecular Medicine, Gustave Roussy Research Center, Université Paris Saclay, 94800 Villejuif, France; bLaboratory of Preclinical Investigations, Translational Research Department, Institut Curie, Université Paris-Sciences-et-Lettres, 75005 Paris, France; cBioPôle Alfort, Ecole Nationale Vétérinaire d’Alfort, 94700 Maisons Alfort, France; dInstitut Curie, Université Paris-Sciences-et-Lettres, Mines ParisTech, Bioinformatics and Computational Systems Biology of Cancer, 75005 Paris, France; eINSERM U900, Unit of Biometry, Institut Curie, Université Paris- Sciences-et-Lettres, 75005 Paris, France; fAssistance Publique Hopitaux de Paris Molecular Oncology Unit, Hôpital Saint Louis, Paris Diderot University, 75010 Paris, France; gDepartment of Medical Oncology, Gustave Roussy Research Center, 94800 Villejuif, France; and hMedical Oncology Department, Institut Curie, Saint Cloud Hospital, Université Paris Descartes, Sorbonne Paris Cité, 75005 Paris, France Edited by Rakesh K. Jain, Massachusetts General Hospital, Boston, MA, and approved October 14, 2019 (received for review June 24, 2019) Predictive
[Show full text]